Labrada DA

Language: Spanish
References: 16
Page: 1-9
PDF size: 131.05 Kb.

ABSTRACT

Introduction: Cystic fibrosis is a genetic disease that is a frequent cause of severe chronic lung disease in young adults. It is associated with biliary tract cirrhosis and gallstones, a reason why the anesthesiologist must be familiar with the clinical characteristics of the disease in order to reduce the rate of perioperative complications that may occur.
Objective: To present the clinical characteristics and perioperative behavior in a patient diagnosed with cystic fibrosis announced for videolaparoscopic cholecystectomy.
Clinical case: Female patient of 19 years of age, black race, with multiple respiratory infections during childhood, who was diagnosed as a new case of cystic fibrosis. During the studies, symptomatic vesicular lithiasis was observed, that’s why the patient what was announced for videolaparoscopic cholecystectomy. The evaluation and preoperative preparation, as well as the intraoperative anesthetic behavior are described.
Conclusions: Anesthetic outcomes depend on the attention to a complex disease that affects multiple organs and the close control and timely treatment of previous lung disease.

REFERENCES

1. Fielbaum O. Updated treatment of cystic fibrosis. Rev Med Clin. Condes. 2017;28(1):60-71.

2. Razón R, Rodríguez F, Rojo M, González JA, Abreu G, Pérez T, et al. La fibrosis quística en Cuba. Informe Nacional Comisión Cubana de Fibrosis Quística. 2008.

3. Jones A, Bilton D, Evans TW. Predictors of outcome in patients with cystic fibrosis requiring endotracheal intubation. Respirology. 2013;18:630-6.

4. Moyer K, Balistreri W. Hepatobiliary disease in patients with cystic fibrosis. Curr Opin Gastroenterol. 2009;25(3):272-8.

5. Karlet MC. An update on cystic fibrosis and implications for anesthesia. AANA J. 2000;68(2):141-8.

6. Labrada A. Patrón ventilatorio en pacientes con enfermedad pulmonar obstructiva crónica para colecistectomía laparoscópica. Rev Cub Anest Rean. 2015 [citado 17/11/2017]. Disponible en: http://www.bvs.sld.cu/revistas/scar/vol14_3_15/scar02315.htm

7. Langton Hewer SC, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev. 2009;4:CD004197. [PMID: 19821321].

8. Gershman AJ, Mehta AC, Infeld M. Cystic fibrosis in adults: An overview for the internist. Cleve Clin J Med. 2006;73:1065-74.

9. Flume PA, Mogayzel PJ Jr, Robinson KA. Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax. Am J Respir Crit Care Med. 2010;182:298-306.

10. Ketchell I. Patients with cystic fibrosis should be intubated and ventilated. Journal of the Royal Society of Medicine. 2010:103:20-24.

11. Kioumis IP, Zarogoulidis K, Huang H, Li Q, Dryllis G, Pitsiou G, et al. Pneumothorax in cystic fibrosis.J Thorac Dis. 2014;6(4):480-87.

12. Yankaskas JR, Marshall BC, Sufian B. Cystic fibrosis adult care: Consensus conference report. Chest. 2004;125:1-39.

13. Saiman L, Marshall BC, Mayer-Hamblett N. Azithromycin inpatients with cystic fibrosis chronically infected with Pseudomonasaeruginosa: A randomized controlled trial. JAMA. 2003;290:1749-56.

14. Suárez M, Ramírez MC, Rodríguez Y, Harteman N, Rodríguez H. Evaluación nutricional de pacientes con fibrosis quística. MEDISAN. 2013;17(4):661-68.

15. Reeves EP, Molloy K, Pohl K, McElvaney NG. Hypertonic saline in treatment of pulmonary disease in cystic fibrosis. Scientific World Journal. 2012;2012:465230. DOI: 10.1100/2012/465230.

16. Wiehe M, Arndt K. Cystic fibrosis: a systems review. AANA J. 2010;78(3):246-51.